Repatha is an effective medication that can lower LDL cholesterol and significantly reduce the risk of heart attacks and strokes. Like most drugs, Repatha can cause side effects. However long-term ...

Praluent and Repatha both lower bad cholesterol in certain people but have different approved uses and age limits. These drugs can have side effects like cold-like symptoms and injection site ...

Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...

Repatha can be given once or twice a month, while Leqvio is given every six months after the first year. Leqvio must be given by a healthcare professional, but Repatha can be injected at home. Repatha ...

Port fuel injection (PFI) was a major milestone in the early '80s. The integration of PFI rapidly changed the way fuel was delivered by increasing fuel economy and improving engine performance. Even ...

Every 40 seconds, someone in the U.S. has a heart attack or stroke, and in most cases, it’s their first. 1 The good news? The risk for these devastating events can actually be significantly reduced by ...

Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more. Got a confidential news tip?

Merck's new pill, enlicitide, and Amgen's longtime Repatha shot are showing heart attack risk-lowering potential, and researchers have made progress on the gene-editing front. The New York Times: New ...

Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results from a ...

(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...